Pharmetheus at PAGE 2026

Note: This event has passed. For upcoming events, please visit the Events page.

Scientific contributions

Wed, Jun 3, 2026, 10:30 – 12:00

I-072:

Food effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approach

Vrenken P, Lambert M, Mezzalana E, Eriksson J, Fouliard S, Sjögren E.

I-086:

Direct and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate elimination

Klose M, Marschner D, Knott M, Wendler J, Müller-Kühnle J, Kovar L, Nyhoegen C, Hartung N, Huisinga W, Michelet R, Mc Laughlin AM, Illerhaus G, Kloft C.

I-095:

Apparent time dependence and rethinking random effect under single time-to-event models

Bergstrand M, Friberg LE, Man P, Liu H.

Wed, Jun 3, 2026, 15:20 – 16:50

II-032:

A mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucel

Mc Laughlin AM, Bergstrand M, Kanska J, Ruiz-Garcia A, Filosto S, Shen R.

II-046:

Model-informed fixed dosing of rozanolixizumab in gMG: PK/PD advantages and comparison from other FcRn blockers

Lledó-García R, Björnsson M.

II-057:

The use of full random effect models (FREM) in model informed precision dosing (MIPD)

Dimitriou M, Jönsson S, Nyberg J, Jonsson EN.

II-061:

Visual predictive checks for real-world data using propensity-score-matching

Keizer R, Bergstrand M, Hughes JH.

II-101:

Use AUC and discard Cmax in exposure-response analyses: a global sensitivity and stochastic simulation-estimation study

Brekkan A, Le Louedec F, Bergstrand M, Jonsson EN.

Thu, Jun 4, 2026, 09:50 – 11:20

III-001:

Model-informed pediatric drug development for clevidipine

Carrara L, Ayoun Alsoud R, Wijk M, Neldemo I, Smania G, Ginocchio V, Bergstrand M, Germani M.

III-093:

A structured approach to pharmacometric covariate modelling: why the estimand is the first decision and the method the second

Jonsson EN, Jönsson S, Hansson E, Nyberg J.

III-103:

The decision-equivalence metric (DEM) method based evaluation of biomarker surrogacy in MASH

Vasyutin I, Glatard A, Stübler S, Fleury A, Schoelch C, Wojtyniak JG.

Software demonstration
S-04:

Rock and roll – deliverables driven by standardized data specifications

Freiberga S, Hellner J, Etté G, Gaby A, Prusis P, Suddapalli M.

Thu, Jun 4, 2026, 13:40 – 15:10

IV-056:

Implementing a full random effects model (FREM) workflow in R using the saemix package

Lavalley-Morelle A, Jonsson EN.

IV-059:

Reference-corrected VPCs: addressing model evaluation challenges with real-world data and adaptive designs

Bergstrand M, Ibrahim MMA, Hughes JH, Keizer RJ.

IV-073:

Population pharmacokinetics and exposure-response analyses of navepegritide in children with achondroplasia

Timmermann S, Aguiar Zdovc J, van Eijk M, Clement Freiberg L, Carlsson Petri KC.

IV-097:

Benchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observations

Selvaggio G, Pellowe M, Sjögren E.

IV-104I:

Usage and regulatory acceptance of PBPK models in paediatric drug applications: a review of EMA public assessment reports

Yu C, Ursino M, Retout S, Chenel M, Comets E, Cleary Y

We’d love to meet you – use this form to book a meeting with us